JP2007530493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530493A5 JP2007530493A5 JP2007504367A JP2007504367A JP2007530493A5 JP 2007530493 A5 JP2007530493 A5 JP 2007530493A5 JP 2007504367 A JP2007504367 A JP 2007504367A JP 2007504367 A JP2007504367 A JP 2007504367A JP 2007530493 A5 JP2007530493 A5 JP 2007530493A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lower alkyl
- unsubstituted
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 7
- -1 methylpyrrolyl Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000008447 perception Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- XCVDGQBGMARFRY-GFCCVEGCSA-N (2r)-2-acetamido-n-[(3-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC(F)=C1 XCVDGQBGMARFRY-GFCCVEGCSA-N 0.000 claims 1
- PVNGTPGYSFGJIH-GFCCVEGCSA-N (2r)-2-acetamido-n-[(4-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=C(F)C=C1 PVNGTPGYSFGJIH-GFCCVEGCSA-N 0.000 claims 1
- SGBCQENKTXKIRD-MRXNPFEDSA-N (2r)-2-acetamido-n-benzyl-2-phenylacetamide Chemical compound O=C([C@H](NC(=O)C)C=1C=CC=CC=1)NCC1=CC=CC=C1 SGBCQENKTXKIRD-MRXNPFEDSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55649904P | 2004-03-26 | 2004-03-26 | |
| EP04007360A EP1579858A1 (en) | 2004-03-26 | 2004-03-26 | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| PCT/EP2005/003176 WO2005092313A1 (en) | 2004-03-26 | 2005-03-24 | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530493A JP2007530493A (ja) | 2007-11-01 |
| JP2007530493A5 true JP2007530493A5 (https=) | 2008-04-10 |
Family
ID=34854637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504367A Pending JP2007530493A (ja) | 2004-03-26 | 2005-03-24 | 痛みのある糖尿病性神経障害における疼痛を治療するためのペプチド化合物の新規使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060100157A1 (https=) |
| EP (2) | EP1579858A1 (https=) |
| JP (1) | JP2007530493A (https=) |
| CN (1) | CN1938010B (https=) |
| AU (1) | AU2005226928B2 (https=) |
| BR (1) | BRPI0509211A (https=) |
| CA (1) | CA2558311A1 (https=) |
| EA (1) | EA012176B1 (https=) |
| MX (1) | MXPA06010995A (https=) |
| NZ (1) | NZ549668A (https=) |
| SG (1) | SG151309A1 (https=) |
| TW (1) | TW200701977A (https=) |
| UA (1) | UA90467C2 (https=) |
| WO (1) | WO2005092313A1 (https=) |
| ZA (1) | ZA200607269B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1243262T3 (da) | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
| ES2185606T3 (es) | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| JP4664924B2 (ja) | 2003-12-02 | 2011-04-06 | ウーツェーベー ファルマ ゲーエムベーハー | 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用 |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| KR20070007931A (ko) | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| PL1781276T3 (pl) | 2004-08-27 | 2010-11-30 | Ucb Pharma Gmbh | Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US7902401B2 (en) * | 2006-12-14 | 2011-03-08 | Nps Pharmaceuticals, Inc. | Fluorinated compounds |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| JP2009539792A (ja) * | 2006-06-08 | 2009-11-19 | シュヴァルツ・ファーマ・アーゲー | 疼痛の医学的状態のための治療組合せ |
| EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| WO2007144195A2 (en) | 2006-06-15 | 2007-12-21 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
| CA2672494A1 (en) * | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| CA2774569A1 (en) * | 2009-09-23 | 2011-03-31 | The University Of North Carolina At Chapel Hill | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| MX350056B (es) | 2009-11-03 | 2017-08-25 | Lupin Ltd | Formulacion de liberacion modificada de lacosamida. |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| MX2013005974A (es) | 2010-12-02 | 2013-07-29 | Ucb Pharma Gmbh | Formulacion de lacosamida de administracion una vez al dia. |
| CN109069480A (zh) | 2015-12-30 | 2018-12-21 | 阿达玛斯医药公司 | 用于治疗与癫痫相关的病症的方法和组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378729A (en) * | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5585358A (en) * | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| US6589994B1 (en) * | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| DK1311256T3 (da) * | 2000-08-17 | 2005-11-28 | Teva Pharma | Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser |
| AU8676301A (en) * | 2000-08-25 | 2002-03-04 | Res Corp Technologies Inc | New uses for amino acid anticonvulsants |
| DK1243262T3 (da) * | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
| ES2185606T3 (es) * | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| JP4664924B2 (ja) * | 2003-12-02 | 2011-04-06 | ウーツェーベー ファルマ ゲーエムベーハー | 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用 |
| US20060009384A1 (en) * | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| KR20070007931A (ko) * | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
| EP1604654A1 (en) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604656A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
-
2004
- 2004-03-26 EP EP04007360A patent/EP1579858A1/en not_active Withdrawn
-
2005
- 2005-03-24 JP JP2007504367A patent/JP2007530493A/ja active Pending
- 2005-03-24 NZ NZ549668A patent/NZ549668A/en unknown
- 2005-03-24 CA CA002558311A patent/CA2558311A1/en not_active Abandoned
- 2005-03-24 AU AU2005226928A patent/AU2005226928B2/en not_active Ceased
- 2005-03-24 WO PCT/EP2005/003176 patent/WO2005092313A1/en not_active Ceased
- 2005-03-24 MX MXPA06010995A patent/MXPA06010995A/es active IP Right Grant
- 2005-03-24 SG SG200902059-5A patent/SG151309A1/en unknown
- 2005-03-24 UA UAA200610139A patent/UA90467C2/ru unknown
- 2005-03-24 EA EA200601777A patent/EA012176B1/ru not_active IP Right Cessation
- 2005-03-24 CN CN2005800097824A patent/CN1938010B/zh not_active Expired - Fee Related
- 2005-03-24 BR BRPI0509211-6A patent/BRPI0509211A/pt not_active IP Right Cessation
- 2005-03-24 EP EP05716372A patent/EP1737437A1/en not_active Withdrawn
- 2005-03-25 US US11/089,441 patent/US20060100157A1/en not_active Abandoned
- 2005-07-11 TW TW094123447A patent/TW200701977A/zh unknown
-
2006
- 2006-08-31 ZA ZA200607269A patent/ZA200607269B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530493A5 (https=) | ||
| JP2008501760A5 (https=) | ||
| JP2008501753A5 (https=) | ||
| JP2007532607A5 (https=) | ||
| JP2008503533A5 (https=) | ||
| EP2827859B1 (en) | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
| JP2008510758A5 (https=) | ||
| JP2009545521A5 (https=) | ||
| CA2566301A1 (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
| US20090018198A1 (en) | Method for treating a motoneuron disorder | |
| JP2010540519A5 (https=) | ||
| JP2010530431A5 (https=) | ||
| JP2004519469A5 (https=) | ||
| BRPI0912607A2 (pt) | medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete | |
| EA200500583A1 (ru) | Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение | |
| JP2012515184A5 (https=) | ||
| JP2015503540A5 (https=) | ||
| JP2002522485A5 (https=) | ||
| PT1365787E (pt) | Utilização de anticonvulsivantes de aminoácidos para tratamento da dor. | |
| US20150005252A1 (en) | Combination therapy for the treatment of cancer | |
| JP2010514834A5 (https=) | ||
| EA201100916A1 (ru) | Комбинация инсулина с триазиновыми производными и их применение для лечения диабета | |
| RU2010151631A (ru) | Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application |